Institute for Research in Biomedicine
Gate2Brain: Peptide Shuttles for the Delivery of Drugs to the Brain
Gate2Brain shuttle peptides represent salvage for new or previously rejected CNS drug candidates by providing a way to cross the blood-brain barrier, BBB.
Gate2Brain technology consist on a toolbox of peptides able to cross the BBB and carry compounds covalently attached (including small molecules, peptides, proteins, antibodies, plasmids, siRNA or mRNA loaded nanoparticles, etc…) that cannot cross this barrier unaided. They have proofed to carry these cargoes in vitro and in vivo. These peptide shuttles use the existing transport mechanisms at the BBB without affecting the normal functioning of these mechanisms and preserving brain homeostasis.
By improving the delivery of therapeutic candidate to the CNS, we will ensure immediate impact in many CNS diseases patients. In addition, in a broader perspective, Gate2Brain technology may help to repurpose existing therapies previously rejected because of difficulty to reach the brain, accelerating the translation towards clinical development. Gate2Brain will also result in the application of lower concentrations of therapeutic agent, thereby significantly lowering systemic side effects and reducing the cost of the treatment.
Gate2Brain peptides combine protease resistance, capacity to carry a wide range of cargoes thanks to their versatility, low production costs, and low immunogenic risk. They provide a non-invasive, non-antigenic, permeable, stable, soluble and receptor-specific way to transport drugs across the BBB and into the CNS.
AffiliationsInstitute for Research in Biomedicine, IRB Barcelona, Baldiri Reixac 1-10, 08028 Barcelona, Spain
1 B. Oller-Salvia et al., Chem. Soc. Rev., 2016, 45, 4690-4707.
2 M. Sánchez-Navarro et al., Curr. Opin. Chem. Biol., 2017, 38, 134-140.
3 M. Sánchez-Navarro et al., Acc. Chem. Res., 2017, 50, 1847-1854.
4 R. Prades et al., Angew. Chem. Int. Ed., 2015, 54, 3967-3972.
5 B. Oller-Salvia et al., Angew. Chem. Int. Ed., 2016, 55, 572-575.
Dr. Teixidó’s major interests are in the field of peptide synthesis and the discovery of peptide shuttles able to reach the brain and increase the transport of a wide range of cargoes including drugs, nanoparticles or diagnostic agents. With this aim, she is developing a toolbox of protease resistant BBB-shuttle peptides, mass spectrometry techniques and transport evaluation tools to be used to discover new shuttles that will improve the delivery of cargoes to the brain.
Meritxell Teixidó has published around 50 scientific articles and reviews and she has participated in 7 patents. In 2007 she won the American Peptide Idol first prize at the 20th American Peptide Symposium in Montreal, Canada. Since 2010 she is the national representative in the European Peptide Society Council and Chairperson of the next 36th EPS, European Peptide Symposium, and 12th IPS, International Peptide Symposium, Barcelona, Sept 2020.